These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 15871033

  • 1. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
    De Cock E, Hutton J, Canney P, Body JJ, Barrett-Lee P, Neary MP, Lewis G.
    Support Care Cancer; 2005 Dec; 13(12):975-86. PubMed ID: 15871033
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Cost-effectiveness of oral ibandronate, i.v. zoledronic acid and i.v. generic pamidronate in the management of metastatic bone disease in breast cancer patients: two parallel studies].
    Schivazappa C, Berto P, Baldini E, Barni S, Dauria G, Cortesi E.
    Recenti Prog Med; 2008 Jan; 99(1):27-31. PubMed ID: 18389868
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic.
    Cristino J, Finek J, Jandova P, Kolek M, Pásztor B, Giannopoulou C, Qian Y, Brezina T, Lothgren M.
    J Med Econ; 2017 Aug; 20(8):799-812. PubMed ID: 28485692
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
    Gordon DH.
    Clin Breast Cancer; 2005 Jun; 6(2):125-31. PubMed ID: 16001990
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.
    Snedecor SJ, Carter JA, Kaura S, Botteman MF.
    Clin Ther; 2012 Jun; 34(6):1334-49. PubMed ID: 22578308
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
    Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A, Culver KW.
    J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis.
    Snedecor SJ, Carter JA, Kaura S, Botteman MF.
    J Med Econ; 2013 Oct; 16(1):19-29. PubMed ID: 22870908
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
    Shapiro CL, Moriarty JP, Dusetzina S, Himelstein AL, Foster JC, Grubbs SS, Novotny PJ, Borah BJ.
    J Clin Oncol; 2017 Dec 10; 35(35):3949-3955. PubMed ID: 29023215
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.